T1	Participants 49 119	EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6)
T2	Participants 269 325	patients with EGFR mutation-positive lung adenocarcinoma
T3	Participants 432 564	patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma were enrolled in LUX-Lung 3 (n=345) and LUX-Lung 6 (n=364)
T4	Participants 3459 3493	patients with del19 EGFR mutations
T5	Participants 3537 3561	Leu858Arg EGFR mutations
T6	Participants 3576 3603	EGFR del19-positive disease
T7	Participants 3627 3653	Leu858Arg-positive disease
